Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:OBSV NASDAQ:PRTG NASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$2.49-2.7%$2.40$2.06▼$17.10$7.82M-0.27591,391 shs205,935 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs1,393 shsPRTGPortage Biotech$7.63+9.6%$7.70$2.81▼$23.01$8.01M0.2556,380 shs377,941 shsSLRXSalarius Pharmaceuticals$4.52+15.0%$6.01$3.64▼$108.00$2.31M0.44170,263 shs890,701 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro+1.19%+8.47%+10.34%-13.22%-82.86%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PRTGPortage Biotech0.00%0.00%0.00%+28.67%+38.48%SLRXSalarius Pharmaceuticals+1.03%+3.42%-16.56%-66.84%-81.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$2.49-2.7%$2.40$2.06▼$17.10$7.82M-0.27591,391 shs205,935 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs1,393 shsPRTGPortage Biotech$7.63+9.6%$7.70$2.81▼$23.01$8.01M0.2556,380 shs377,941 shsSLRXSalarius Pharmaceuticals$4.52+15.0%$6.01$3.64▼$108.00$2.31M0.44170,263 shs890,701 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro+1.19%+8.47%+10.34%-13.22%-82.86%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%PRTGPortage Biotech0.00%0.00%0.00%+28.67%+38.48%SLRXSalarius Pharmaceuticals+1.03%+3.42%-16.56%-66.84%-81.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$42.001,586.75% UpsideOBSVObsEva 0.00N/AN/AN/APRTGPortage Biotech 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLRX, PRTG, ALZN, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ALZNAlzamend NeuroWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/25/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $42.008/21/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.00 ➝ $45.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/APRTGPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/A$14.31 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51MN/A0.00N/AN/AN/A-151.24%-124.17%12/10/2025 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/APRTGPortage Biotech-$6.77M-$41.65N/A∞N/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals-$5.58M-$43.48N/A∞N/AN/A-556.47%-192.35%11/13/2025 (Estimated)Latest SLRX, PRTG, ALZN, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLRXSalarius Pharmaceuticals-$33.00-$0.45+$32.55-$0.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A6.036.03OBSVObsEvaN/A0.610.61PRTGPortage BiotechN/A2.022.02SLRXSalarius PharmaceuticalsN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%OBSVObsEva17.52%PRTGPortage Biotech13.36%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro30.21%OBSVObsEva14.40%PRTGPortage Biotech42.07%SLRXSalarius Pharmaceuticals1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.14 million2.19 millionNo DataOBSVObsEva5077.97 million66.74 millionNot OptionablePRTGPortage Biotech61.05 million608,000OptionableSLRXSalarius Pharmaceuticals20510,000504,000Not OptionableSLRX, PRTG, ALZN, and OBSV HeadlinesRecent News About These CompaniesSalarius regains compliance with Nasdaq min bid price requirementSeptember 9, 2025 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 9, 2025 | finanznachrichten.deSalarius Pharmaceuticals Regains Nasdaq Compliance with Minimum Bid Price RequirementSeptember 9, 2025 | quiverquant.comQSalarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 9, 2025 | globenewswire.comSalarius Pharmaceuticals Files Prospectus for Stock OfferingAugust 27, 2025 | msn.comSalarius Pharmaceuticals Inc (SLRX) - Investing.comAugust 20, 2025 | investing.comSalarius Pharmaceuticals Appoints New Acting CEOAugust 19, 2025 | msn.comSalarius Pharmaceuticals files $50M mixed securities shelfAugust 16, 2025 | msn.comSalarius Pharmaceuticals trading halted, news pendingAugust 16, 2025 | msn.comSalarius Pharmaceuticals Announces Reverse Stock SplitAugust 16, 2025 | msn.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | finanznachrichten.deSalarius Pharmaceuticals Announces 1-for-15 Reverse Stock SplitAugust 14, 2025 | globenewswire.comSalarius Pharmaceuticals Raises $3.8M Through Stock SaleJuly 31, 2025 | msn.comSalarius Pharmaceuticals Modifies Security Holders’ RightsJuly 30, 2025 | msn.comSalarius Pharmaceuticals stock soars after Nasdaq extends compliance deadlineJuly 29, 2025 | investing.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity StandardJuly 14, 2025 | finance.yahoo.comSalarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity StandardJuly 14, 2025 | globenewswire.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role ...July 11, 2025 | morningstar.comMSalarius Pharmaceuticals shareholders approve reverse stock split and share issuanceJuly 10, 2025 | uk.investing.comSalarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published StudiesJuly 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLRX, PRTG, ALZN, and OBSV Company DescriptionsAlzamend Neuro NASDAQ:ALZN$2.49 -0.07 (-2.73%) Closing price 04:00 PM EasternExtended Trading$2.48 -0.02 (-0.60%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Portage Biotech NASDAQ:PRTG$7.63 +0.67 (+9.63%) Closing price 09/3/2025Extended Trading$7.63 0.00 (0.00%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Salarius Pharmaceuticals NASDAQ:SLRX$4.52 +0.59 (+15.01%) Closing price 04:00 PM EasternExtended Trading$4.36 -0.16 (-3.54%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
